Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness
1
National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan
2
Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 300044, Taiwan
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 626; https://doi.org/10.3390/vaccines8040626
Received: 19 August 2020 / Revised: 11 October 2020 / Accepted: 16 October 2020 / Published: 25 October 2020
(This article belongs to the Special Issue Influenza Virus and Vaccine Development)
The embryonated egg-based platform currently produces the majority of seasonal influenza vaccines by employing a well-developed master donor virus (MDV, A/PR/8/34 (PR8)) to generate high-growth reassortants (HGRs) for A/H1N1 and A/H3N2 subtypes. Although the egg-based platform can supply enough seasonal influenza vaccines, it cannot meet surging demands during influenza pandemics. Therefore, multi-purpose platforms are desirable for pandemic preparedness. The Vero cell-based production platform is widely used for human vaccines and could be a potential multi-purpose platform for pandemic influenza vaccines. However, many wild-type and egg-derived influenza viruses cannot grow efficiently in Vero cells. Therefore, it is critical to develop Vero cell-derived high-growth MDVs for pandemic preparedness. In this study, we evaluated two in-house MDVs (Vero-15 and VB5) and two external MDVs (PR8 and PR8-HY) to generate Vero cell-derived HGRs for five avian influenza viruses (AIVs) with pandemic potentials (H5N1 clade 2.3.4, H5N1 clade 2.3.2.1, American-lineage H5N2, H7N9 first wave and H7N9 fifth wave). Overall, no single MDV could generate HGRs for all five AIVs, but this goal could be achieved by employing two in-house MDVs (vB5 and Vero-15). In immunization studies, mice received two doses of Vero cell-derived inactivated H5N1 and H7N9 whole virus antigens adjuvanted with alum and developed robust antibody responses.
View Full-Text
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 692 KiB)
MDPI and ACS Style
Chen, P.-L.; Tzeng, T.-T.; Hu, A.Y.-C.; Wang, L.H.-C.; Lee, M.-S. Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness. Vaccines 2020, 8, 626. https://doi.org/10.3390/vaccines8040626
AMA Style
Chen P-L, Tzeng T-T, Hu AY-C, Wang LH-C, Lee M-S. Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness. Vaccines. 2020; 8(4):626. https://doi.org/10.3390/vaccines8040626
Chicago/Turabian StyleChen, Po-Ling; Tzeng, Tsai-Teng; Hu, Alan Y.-C.; Wang, Lily H.-C.; Lee, Min-Shi. 2020. "Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness" Vaccines 8, no. 4: 626. https://doi.org/10.3390/vaccines8040626
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit